Hoe verhoudt STAR's PE Ratio zich tot zijn concurrenten?

STAR is duur op basis van de Price-To-Earnings -ratio ( 78.1 x) vergeleken met het gemiddelde van de peer ( 32.2 x).

Hoe verhoudt STAR's PE Ratio zich tot andere bedrijven in de IN Pharmaceuticals industrie?

STAR is duur op basis van de Price-To-Earnings -ratio ( 78.1 x) vergeleken met het Indian Pharmaceuticals -industriegemiddelde ( 32.2 x).

Wat is STAR's PE Ratio vergeleken met zijn Fair PE Ratio? Dit is de verwachte PE Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

STAR is duur op basis van de Price-To-Earnings Ratio ( 78.1 x) vergeleken met de geschatte Fair Price-To-Earnings Ratio ( 58.4 x).

Wat is de reële prijs van STAR als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

STAR ( ₹1503.65 ) wordt verhandeld onder onze schatting van [[eerlijke waarde]] ( ₹1651.02 )

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

De koersdoelstelling is minder dan 20 % hoger dan de huidige aandelenkoers.

Strides Pharma Science (NSEI:STAR) - Aandelenkoers, Nieuws & Analyse

STAR Overzicht aandelen

Strides Pharma Science Limited ontwikkelt, produceert en verkoopt farmaceutische producten in Afrika, Australië, Noord-Amerika, Europa, Azië en India. Meer informatie

STAR fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	4/6
Prestaties in het verleden	2/6
Financiële gezondheid	3/6
Dividenden	1/6

Beloningen

Verhandeld tegen 8.9% onder onze schatting van de reële waarde

De winst zal naar verwachting met 45.62% per jaar groeien

Dit jaar winstgevend geworden

Risicoanalyse

Rentebetalingen worden niet goed gedekt door de winsten

Strides Pharma Science Limited Concurrenten

Granules India

BSE:532482

₹133.7b

Glenmark Life Sciences

NSEI:GLS

₹132.7b

Caplin Point Laboratories

BSE:524742

₹148.3b

Marksans Pharma

NSEI:MARKSANS

₹138.4b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Strides Pharma Science
Historische aandelenkoersen
Huidige aandelenkoers	₹1,503.65
52 Week Hoogtepunt	₹1,675.00
52 Week Laag	₹482.00
Bèta	0.73
11 maand verandering	-3.22%
3 maanden verandering	15.31%
1 Jaar Verandering	203.61%
33 jaar verandering	197.63%
5 jaar verandering	287.14%
Verandering sinds IPO	67.88%

Recent nieuws en updates

Strides Pharma Science's (NSE:STAR) Solid Earnings Are Supported By Other Strong Factors

Nov 01

Why Investors Shouldn't Be Surprised By Strides Pharma Science Limited's (NSE:STAR) 27% Share Price Surge

Oct 21

Recent updates

Strides Pharma Science's (NSE:STAR) Solid Earnings Are Supported By Other Strong Factors

Nov 01

Why Investors Shouldn't Be Surprised By Strides Pharma Science Limited's (NSE:STAR) 27% Share Price Surge

Oct 21

After Leaping 29% Strides Pharma Science Limited (NSE:STAR) Shares Are Not Flying Under The Radar

Aug 14

Investors Still Waiting For A Pull Back In Strides Pharma Science Limited (NSE:STAR)

Apr 04

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Feb 29

Strides Pharma Science Limited's (NSE:STAR) Shares Leap 31% Yet They're Still Not Telling The Full Story

Dec 23

We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt

Sep 26

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Jun 08

Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Aug 02

Is Strides Pharma Science (NSE:STAR) A Risky Investment?

Jun 25

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Dec 21

Strides Pharma Science (NSE:STAR) Has Announced That It Will Be Increasing Its Dividend To ₹2.50

Jul 28

Estimating The Fair Value Of Strides Pharma Science Limited (NSE:STAR)

Apr 13

Should Strides Pharma Science Limited (NSE:STAR) Be Part Of Your Dividend Portfolio?

Mar 04

These 4 Measures Indicate That Strides Pharma Science (NSE:STAR) Is Using Debt Extensively

Feb 15

Can Mixed Fundamentals Have A Negative Impact on Strides Pharma Science Limited (NSE:STAR) Current Share Price Momentum?

Jan 26

The Strides Pharma Science (NSE:STAR) Share Price Is Up 140% And Shareholders Are Boasting About It

Jan 11

Rendement voor aandeelhouders

	STAR	IN Pharmaceuticals	IN Markt
7D	6.2%	-0.2%	0.3%
1Y	203.6%	40.5%	27.3%

Rendement versus industrie: STAR overtrof de Indian Pharmaceuticals industrie, die het afgelopen jaar een rendement 40.5 % opleverde.

Rendement versus markt: STAR overtrof de Indian markt, die het afgelopen jaar een rendement opleverde van 27.3 %.

Prijsvolatiliteit

Is STAR's price volatile compared to industry and market?
STAR volatility
STAR Average Weekly Movement	5.0%
Pharmaceuticals Industry Average Movement	6.0%
Market Average Movement	6.1%
10% most volatile stocks in IN Market	9.2%
10% least volatile stocks in IN Market	4.0%

Stabiele aandelenkoers: STAR heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van STAR is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1990	3,065	Badree Komandur	www.strides.com

Strides Pharma Science Limited ontwikkelt, produceert en verkoopt farmaceutische producten in Afrika, Australië, Noord-Amerika, Europa, Azië en India. Het bedrijf is actief in twee segmenten, Farmaceutica en Biofarmaceutica. Het bedrijf biedt farmaceutische generieke producten in verschillende vormen, zoals tabletten, harde en zachte gelatine capsules, sachets en vloeistoffen, evenals neusspray, gels, poeders, vaste stoffen, zalven en crèmes.

Strides Pharma Science Limited Samenvatting

Hoe verhouden de winst en inkomsten van Strides Pharma Science zich tot de beurswaarde?
STAR fundamentele statistieken
Marktkapitalisatie	₹128.02b
Inkomsten(TTM)	₹1.77b
Inkomsten(TTM)	₹44.10b

78.1x

Koers/Winstverhouding

3.1x

P/S-verhouding

Is STAR overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
STAR resultatenrekening (TTM)
Inkomsten	₹44.10b
Kosten van inkomsten	₹19.25b
Brutowinst	₹24.85b
Overige uitgaven	₹23.08b
Inkomsten	₹1.77b

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	19.25
Brutomarge	56.35%
Nettowinstmarge	4.01%
Schuld/Eigen Vermogen Verhouding	100.0%

Hoe presteerde STAR op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

0.2%

Huidig dividendrendement

-18%

Uitbetalingsratio

STAR Overzicht aandelen

Beloningen

Risicoanalyse

Strides Pharma Science Limited Concurrenten

BSE:532482

₹133.7b

NSEI:GLS

₹132.7b

BSE:524742

₹148.3b

NSEI:MARKSANS

₹138.4b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Strides Pharma Science's (NSE:STAR) Solid Earnings Are Supported By Other Strong Factors

Second quarter 2025 earnings released: EPS: ₹10.14 (vs ₹14.54 loss in 2Q 2024)

Why Investors Shouldn't Be Surprised By Strides Pharma Science Limited's (NSE:STAR) 27% Share Price Surge

Strides Pharma Science Limited to Report Q2, 2025 Results on Oct 24, 2024

Upcoming dividend of ₹2.50 per share

Strides Pharma Science Limited, Annual General Meeting, Sep 25, 2024

Recent updates

Strides Pharma Science's (NSE:STAR) Solid Earnings Are Supported By Other Strong Factors

Second quarter 2025 earnings released: EPS: ₹10.14 (vs ₹14.54 loss in 2Q 2024)

Why Investors Shouldn't Be Surprised By Strides Pharma Science Limited's (NSE:STAR) 27% Share Price Surge

Strides Pharma Science Limited to Report Q2, 2025 Results on Oct 24, 2024

Upcoming dividend of ₹2.50 per share

Strides Pharma Science Limited, Annual General Meeting, Sep 25, 2024

After Leaping 29% Strides Pharma Science Limited (NSE:STAR) Shares Are Not Flying Under The Radar

Strides Pharma Science Limited Announces Completion of Tenure of S Sridhar as Independent Director

First quarter 2025 earnings released: EPS: ₹7.64 (vs ₹0.79 loss in 1Q 2024)

Strides Pharma Science Limited to Report Q1, 2025 Results on Jul 29, 2024

Insufficient new directors

New minor risk - Dividend sustainability

Strides Pharma Science Limited Announces Chief Financial Officer Changes, Effective June 1, 2024

Price target increased by 20% to ₹994

Forecast breakeven date pushed back to 2025

Strides Pharma Science Limited to Report Q4, 2024 Results on May 22, 2024

Strides Pharma Science Limited Approves Appointment of Ameet P Hariani as Independent Director

Investors Still Waiting For A Pull Back In Strides Pharma Science Limited (NSE:STAR)

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Price target increased by 10% to ₹730

Third quarter 2024 earnings released: ₹0.49 loss per share (vs ₹8.86 loss in 3Q 2023)

Strides Pharma Science Limited to Report Q3, 2024 Results on Jan 30, 2024

Strides Pharma Science Limited's (NSE:STAR) Shares Leap 31% Yet They're Still Not Telling The Full Story

Strides Pharma Global Pte. Limited Receives USFDA Approval for Generic Suprep®? Bowel Prep Kit

Now 21% undervalued

Strides Pharma Science Limited Announces Change in Management

Second quarter 2024 earnings released: ₹14.54 loss per share (vs ₹0.47 profit in 2Q 2023)

Strides Pharma Science Limited to Report Q2, 2024 Results on Oct 30, 2023

New major risk - Revenue and earnings growth

We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt

Strides Pharma Global Pte. Limited Receives Tentative United States Food & Drug Administration Approval for Dolutegravir Tablets

Strides Pharma Science Limited Announces Resignation of Ankit Gupta as Vice President and Head of Corporate Development and Strategy

Price target increased by 10% to ₹530

Upcoming dividend of ₹1.50 per share at 0.3% yield

Strides Pharma Science Limited to Report Q1, 2024 Results on Aug 02, 2023

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Strides Pharma Science Limited Recommends Dividend for Financial Year Ended March 31, 2023

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Strides Pharma Science Limited to Report Q4, 2023 Results on May 25, 2023

Price target decreased by 7.2% to ₹462

Third quarter 2023 earnings released: ₹8.86 loss per share (vs ₹13.55 loss in 3Q 2022)

Strides Pharma Science Limited to Report Q3, 2023 Results on Jan 24, 2023

Insufficient new directors

Second quarter 2023 earnings released: EPS: ₹2.54 (vs ₹18.12 loss in 2Q 2022)

Insufficient new directors

Strides Pharma Science Limited Announces Resignation of Director

Strides Pharma Science Limited to Report Q2, 2023 Results on Nov 14, 2022

Strides Pharma Science Limited, Annual General Meeting, Sep 09, 2022

Strides Pharma Science Limited, Annual General Meeting, Sep 09, 2022

Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

First quarter 2023 earnings released: ₹15.13 loss per share (vs ₹22.88 loss in 1Q 2022)

Strides Pharma Science Limited to Report Q1, 2023 Results on Jul 29, 2022

Is Strides Pharma Science (NSE:STAR) A Risky Investment?

Stelis Biopharma Limited and Strides Pharma Science Limited Receive the European Union Goods Manufacturing Practices (EU-GMP) Compliance Certificate

Now 20% undervalued after recent price drop

Strides Receives USFDA Approval for Ibuprofen Oral Suspension

Full year 2022 earnings: EPS misses analyst expectations

Strides Pharma Science Limited to Report Q4, 2022 Results on May 24, 2022

Price target decreased to ₹463